Scientists Announce New Drosophila Drug Screen for Fragile X Syndrome
Test Identifies Promising Compounds and Potential Drug Targets
Test Identifies Promising Compounds and Potential Drug Targets
Scientists using a new drug screening method in Drosophila (fruit flies), have identified several drugs and small molecules that reverse the features of fragile X syndrome -- a frequent form of mental retardation and one of the leading known causes of autism. The discovery sets the stage for developing new treatments for fragile X syndrome.
The results of the research by lead scientist Stephen Warren, Ph.D., chair of the Department of Human Genetics at Emory University School of Medicine, are published online in the journal Nature Chemical Biology (subscription required). Read a press release about the study here.
The results of the research by lead scientist Stephen Warren, Ph.D., chair of the Department of Human Genetics at Emory University School of Medicine, are published online in the journal Nature Chemical Biology (subscription required). Read a press release about the study here.
|
|
|
|
|
|
|||||
